Citius Oncology, Inc. reports a Return on Equity (ROE) of -120.53%.

What is CTOR's dividend yield?

Citius Oncology, Inc. offers a dividend yield of 0.00%.

What is CTOR's Quality Score?

Our AI rates CTOR's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CTOR?

Our AI Timing Score for CTOR is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CTOR belong to?

Citius Oncology, Inc. is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

Citius Oncology, Inc. (CTOR) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

CTOR AI Analysis Summary

Our AI summary for CTOR: Citius Oncology, Inc. (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of -120.53%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CTOR

Citius Oncology, Inc.

USD 0.66

0.03 (5.53%) Day Change

Watchlist Portfolio Compare Chart

0.11

D/E

-120.5%

ROE

-42.2%

ROA

0.00%

Div Yield

CITIUS ONCOLOGY, INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.66 Price 0.03 (5.53%) Day Change	NEWS SCORE: 96

CTOR, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	96
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.66
PBV / Sector	1.65 / 10.04
Earning Per Share	-0.48

PE / Sector	N/A / 32.60
PEG or PE/Growth / Sector	N/A / -0.13
Average 1M Daily Value	0.03 M GREAT
Average 1W Daily Value	0.03 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-757.57 / 12.55
NPM Average (%) / Sector	-757.57 / -10.76
NPM Change Average (%) / Sector	N/A / 113.68
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-42.22 / 7.68
ROA Average (%) / Sector	-28.77 / 2.97
ROA Change Average (%) / Sector	17.18 / 111.24 GOOD
ROE (%) / Sector	-120.53 / 25.75
ROE Average (%) / Sector	-60.25 / 14.00
ROE Change Average (%) / Sector	49.24 / 377.43 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.52
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.76

Registration Details

Analyze Date	2026-08-05 08:00:02
Symbol	CTOR
Name	CITIUS ONCOLOGY, INC.
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	92.98 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	58.15 / 10,527.15

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 11 Commerce Drive, Cranford, NJ, United States, 07016

Phone: 908 967 6677

Website: https://citiusonc.com/overview/default.aspx

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.